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Pluripotent stem cellsmay acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by
the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how
the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic
applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should
be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for eval-
uating the risks that they may pose for clinical use.It is remarkable that only 20 years after the first report of
the growth of human embryonic stem cells in vitro and
just 10 years after discovering that somatic cells can be re-
programmed to pluripotency as induced pluripotent stem
cells (iPSCs), the results of the first clinical trials of pluripo-
tent stem cells (PSCs) to treat macular degeneration have
been reported (Mandai et al., 2017; Schwartz et al., 2015;
Song et al., 2015). Indeed, clinical trials of PSCs for a num-
ber of conditions, including spinal cord injury, diabetes,
heart disease, and Parkinson’s disease, are already in prog-
ress or are just on the horizon (Trounson and DeWitt,
2016). Yet translating these initial trials into routine and
safe therapies for the host of conditions for which PSCs
offer new opportunities requires a deep understanding of
PSC biology. The mechanisms controlling PSC behavior
during their in vitro isolation, genetic manipulation (if
necessary), differentiation, and maintenance are not fully
known, and understanding how alterations to these behav-iors could have an impact on their fate upon engraftment
into humans or the appearance of potentially malignant
transformed cells is a requirement for successful stem cell
therapeutics.
The central question addressed at this meeting, orga-
nized by the International Stem Cell Initiative (ISCI),
with support from the UK RegenerativeMedicine Platform,
was: which of the possible genetic and epigenetic changes
that occur in PSCs in vitromight compromise the safety and
efficacy of PSC-derived products for regenerativemedicine?
A diverse group of basic scientists ranging from those with
expertise in somatic cell and cancer genetics, PSC biology,
DNA synthesis and repair, epigenetics and apoptosis, and
sensitive systems for variant detection met with those
developing and seeking to regulate PSC-based regenerative
medicine to discuss this problem.
The genetic changes commonly reported by numerous
groups and documented in an ISCI survey of well overStem Cell Reports j Vol. 9 j 1–4 j July 11, 2017 j 1
Some participants from the meeting explore Acadia National Park. (Photograph courtesy of Adam Hirst, Stem Cell Technologies).
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chromosomal alterations, gains of whole, or parts of, chro-
mosomes 1, 12, 17, and 20, as well as losses of regions of
chromosome 10, 18, and 22. These changes, which appar-
ently provide a selective growth advantage to the variant
cells (Olariu et al., 2010), are readily detected by standard
cytogenetic techniques but only if they are present in
over 10%of the cells in a PSC line (Baker et al., 2016). Other
methods, such as microarray or sequencing analysis, have
also uncovered genomic changes, including copy number
variants (CNVs) and point mutations that arise during
in vitro culture. For example, a short region in the proximal
part of chromosome 20q was amplified in 22 of 79 PSC
lines with an apparently normal G-banded karyotype in
the ISCI survey (Amps et al., 2011). This CNV leads to over-
expression of BCL2L1, with the consequence that these
cells can escape apoptosis (Avery et al., 2013). Mutations
in p53, which were detected by exome sequencing of 117
human PSC lines (Merkle et al., 2017), is also expected to
confer protection against apoptosis (Amir et al., 2017),
providing a selective advantage to the cells in vitro. Recur-
rent appearance of variants that confer a growth or survival
advantage in vitro is a worrisome theme, particularly when
the changes are known to be associated with human can-
cer. Epigenetic changes, including erosion of X chromo-
some inactivation and loss of imprinting, have also been2 Stem Cell Reports j Vol. 9 j 1–4 j July 11, 2017noted in PSCs (Bar et al., 2017; Mekhoubad et al., 2012).
The challenge is to understand what impact these epige-
netic changes might have on cell phenotype, stability,
and growth. One further underexplored consideration is
the extent to which epigenetic changes may contribute
to the likelihood of acquiring genetic variants in PSCs.
With this background in mind, the assembled scientists
at the ISCI meeting set out to discuss three overarching
questions regarding the use of PSCs in clinical medicine:
(1) How should cells be assayed to detect genetic and epige-
netic variants? (2) How can the rate at which variant cells
appear in cultures of PSCs be minimized? (3) How can
the significance of the presence of particular types of
variant cells be assessed as a prelude to ensuring their safety
and efficacy in vivo?
Detecting and Minimizing the Appearance of Variant
Cells
Screening for changes in the genome largely depends on
established techniques, including G-band karyotyping,
fluorescence in situ hybridization, digital PCR, and micro-
arrays, but the limits of detection for karyotypic changes
and CNVs mean that variants may not be noted unless
they are present in at least 10% of the cells in a culture
(Baker et al., 2016). Nevertheless, few studies clearly specify
the limit of detection of their assays when reporting on
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sequencing, now under development, could improve the
sensitivity of detection of abnormalities inmosaic cultures.
Several meeting participants pointed out that genetic
changes that provide a selective advantage, such as those
affecting BCL2L1 or p53 (Avery et al., 2013; Merkle et al.,
2017), often become dominant in a culture in a rather short
period of time, a factor that might mitigate some concerns
over detection sensitivity. However, selective advantage is
likely to be context dependent and may come into play
only once the cells have been differentiated and/or trans-
planted, so that a rare variant that does not expand quickly
in cultures of undifferentiated PSCs may still pose risk.
Minimizing the rates at which variants appear in cultures
of PSCs during scale-up and/or differentiation is a goal
that might, in part, be achieved by manipulating the cul-
ture environment to avoid suboptimal conditions that
select for variants. This requires a detailed understanding
of the mechanisms and dynamics by which different
variant cells gain a growth advantage, information that is
lacking in most cases.
An alternative approach is to minimize the rate at which
mutations arise in PSCs from errors in DNA synthesis and
repair or errors in chromosome segregation at mitosis. Un-
fortunately, the causes andmutation rates for the common
variants in PSCs are unknown and difficult to assess.
Although considerable knowledge and expertise exists
about the maintenance of genetic and epigenetic integrity
in somatic cells and in cancer, we have little knowledge
about the extent to which these mechanisms operate in
PSCs, or whether other mechanisms may apply in these
unique cells. PSCs certainly exhibit distinct cell-cycle regu-
lation and DNA damage responses, probably reflecting the
position in development of the early embryonic cells to
which they correspond. Indeed, PSCs are an anomaly as
they are the only non-transformed diploid cells that can
be maintained indefinitely without apparent senescence.
The Potential Significance of Epigenetic and Genetic
Variants
It is inevitable, however, that genetic variants will be de-
tected in PSC cultures and, as high-resolution genetic
studies continue to accrue, the challenges in interpreting
the biological significance of a growing catalog of genetic
variation will become more acute. For example, in the
earlier ISCI project, we reported that CNVs found in
normal, apparently healthy individuals surveyed in the
HapMap project, also appeared during the culture of
some PSCs, perhaps indicating unstable regions of the
genome (Amps et al., 2011). Further, otherwise healthy in-
dividuals do harbor subpopulations of cells containing ge-
netic variants of unknown significance, as found in studies
of iPSCs derived from skin fibroblasts (Rouhani et al.,2016). A single seemingly pathogenic variant is often not
sufficient to lead to cellular transformation, which often re-
quires multiple changes. Nevertheless, since the common
recurrent changes seen in vitro apparently give a selective
growth advantage to the undifferentiated PSCs, theymight
represent drivermutations capable of promoting teratomas
or tumors of differentiated lineages following transplanta-
tion (Ben-David et al., 2014).
These issues were discussed side by side with presenta-
tions from various groups either conducting or planning
PSC-based clinical trials. Although long-term therapeutic
strategies with PSCs involve transplanting derivative differ-
entiated cells or adult stem cells, not undifferentiated PSCs,
the regulatory requirements for clinical trials discussed at
the meeting tended to focus on demonstrating the absence
of PSCs in the cell preparations to be transplanted. It is
indeed essential to avoid the accidental transplantation
of undifferentiated cells, but the more intractable problem
is the potential impact on safety caused by variants that
lead to malignant transformation, or to some other unde-
sirable change in the particular population of cells required
for therapy. In the absence of knowledge about the effects
of individual genetic variants on specific adult stem cells
or differentiated cell types, existing or proposed strategies
for addressing these problems include transplantation to
easily resectable sites or encapsulation of the transplanted
cells (possible in a few situations such as pancreatic b cells
for treating diabetes), or the use of gene editing to intro-
duce conditional suicide genes to provide a fail-safe strat-
egy for eliminating cells after transplantation if a problem
arose. On the other hand, representatives of the cancer
genomics community pointed out that extensive collabo-
rative studies over the past decade have produced several
atlases that document the bulk of the genetic changes
that give rise to most types of human cancer. This informa-
tion should at least provide some perspective on which ge-
netic alterations in PSC lines would be of greatest concern
for therapy.
The regulatory implications of these safety issues have
been extensively discussed in Japan in relation to trials of
iPSC-derived therapeutics, but there is no current interna-
tional consensus about how they should be addressed.
Indeed, it is important to recognize that in many cases
we currently lack relevant information to allow an appro-
priate assessment of potential risks.
Toward an International Consensus on Risk
Assessment
The recommendation of this meeting was to establish an
international advisory group to collate and curate the
information currently in hand while developing an inter-
national framework for evaluating the risks posed by
genetic and epigenetic variants of PSCs for therapeuticStem Cell Reports j Vol. 9 j 1–4 j July 11, 2017 3
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dependent, taking into account patient age, disease
severity, the specific cell types to be transplanted, and the
sensitivity of the techniques used to characterize the
genome and epigenome of the PSCs and their differenti-
ated derivatives. Knowledge from other spheres, such as
the cancer genome projects, about the function of genes
affected in particular variants, whether they involve copy
number changes, or mutations affecting gene regulation
or function, should also be considered. The advisory group
itself could identify significant knowledge gaps, helping to
direct research efforts into the safety assessment of cell
therapy. Ideally, it would also curate the genomic informa-
tion from cells used for clinical trials as the field develops,
so that a retrospective review of the phenotypic and func-
tional behavior of the transplanted cells, in particular
whether a given variant causes clinical problems, could
be achieved. It was noted that the falling costs of
genome-wide technologies mean that routine screening
of panels of cell lines for subchromosomal genetic variants
is now feasible. Ultimately, given the scale of the issues at
hand, a coordinated international consensus as to the
potential risks posed by the appearance of (epi)genetic var-
iants in PSCs will be necessary to ensure successful realiza-
tion of the therapeutic potential of PSC-based therapies.
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